Group 1 - The core point of the article is that Kangtai Biological (300601) has received a notice of acceptance from the National Medical Products Administration for its application for the marketing authorization of a trivalent influenza virus split vaccine [1] - The trivalent influenza virus split vaccine is part of a broader range of influenza vaccines developed by the company, which includes a quadrivalent influenza virus split vaccine that has already been applied for production registration and a quadrivalent influenza virus split vaccine that has been approved for clinical use for the 6-35 month age group [1] - The vaccine series covers all age groups, indicating the company's comprehensive approach to influenza vaccination [1]